Plenary Session:
211. Closing Plenary Session: Global Resistance
Sunday, October 6, 2013: 8:00 AM-10:00 AM
Room: The Moscone Center: Esplanade Ballroom 301-310
Co-organized with the Center for Global Health Policy

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • review the priority, un-met need areas to address antibiotic resistant infections
  • identify the barriers and solutions to new technology development
  • describe policy recommendations to facilitate prevention and treatment of resistant infections
  • discuss major developments in the evolution of antibiotic-resistant gonorrhea in the last two years
  • describe the rationale for treatment with parenteral cephalosporins for uncomplicated gonorrhea
  • identify at least two other sexually transmitted pathogens in which resistance to standard antimicrobial therapy has been identified
  • idenfity the patterns of emerging malaria resistance and what’s happening with emerging artemesinin resistance in South East Asia
  • explain how practitioners should devise therapy for travelers with malaria from different regions of the world
  • identify new malaria drugs under development now that may replace artemesinin combination therapy (ACT) if resistance becomes widespread

Target Audience: vaccinologists, scientists, researchers, public health practitioners, pharmacists, nurses, microbiologists, members-in-training, lab personnel, investigators, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, hospital administrators, HIV specialists, HIV clinicians, health care workers, fellows, epidemiologists, clinicians, academicians

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Moderator:  James M. Hughes, MD, FIDSA, Emory University

Presentations:

8:00 AM
Malaria Drug Resistance: Caught in the ACT
Wesley Van Voorhis, MD, PhD, FIDSA

9:00 AM
The Future of Antibiotics and Resistance
Brad Spellberg, MD, FIDSA

CME Credits: Maximum of 2.0 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-133-L01-P

Disclosures:

J. M. Hughes, None

W. Van Voorhis, None

J. Marrazzo, None

B. Spellberg, GSK, Cardeas, Meiji, aRigen, Synthetic Biologics: Consultant, Consulting fee
Pfizer, Eisai, Cubist, Cempra, Bristol Myers: Investigator, Grant recipient
Cubist: Independent Contractor, Speaker honorarium

J. Flood, None

See more of: Plenary Session
<< Previous Session | Next Session >>

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.